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ABSTRACT
Malignant neoplasms are associated with a wide range of paraneoplastic rheumatological syndromes. These can be defined as remote 
effects of cancer, which are not caused by the tumor and its metastasis.
The authors describe the case of an 82-year-old man, who presented with a one-month history of pain, stiffness, and functional limitation of 
the scapular and pelvic girdles. Blood tests showed raised levels of inflammatory markers. 
He was diagnosed with Polymyalgia Rheumatica, but the lack of response to corticosteroids led to the suspicion of an alternative diagnosis, 
like, for example, an occult neoplasm. Although patient evaluation was initially normal, five months later he developed macroscopic 
haematuria and was diagnosed with bladder and prostate carcinomas. After surgical treatment, the patient fully recovered from his 
rheumatological syndrome.
LEARNING POINTS
• In cases when polymyalgia rheumatica exhibits atypical clinical features and/or therapeutic resistance, additional investigation is 
recommended.
• Paraneoplastic syndromes can lead to the diagnosis of an underlying neoplasm.
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INTRODUCTION 
Paraneoplastic syndromes are associated with a wide range of diseases and/or symptoms that are not caused directly by the tumour or 
its metastases. They can result from the action of hormones, cytokines, and other substances produced by neoplastic cells, or are the 
consequence of the host’s mechanisms directed against these cells. These manifestations tend to occur at sites that are distant from the 
tumour[1]. Some may consist of a variety of musculoskeletal pathologies, and are, therefore, defined as paraneoplastic rheumatologic 
syndromes.
Polymyalgia rheumatica (PMR), a relatively common disease in the elderly, is characterized by stiffness and pain in the shoulders, neck, and 
hips.
The association between PMR and cancer is controversial, and it is based on temporal concurrence and corresponding clinical course 
between the two pathologies. Associations between PMR and haematological and solid malignant tumours have been described[2]. 
Paraneoplastic syndromes are important as they can represent the first presentation of an associated,and often occult, neoplasm[3]. 
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CASE REPORT
A 82-year-old man was admitted to the Emergency Department with a one-month history of pain, stiffness, and decreased range of motion 
affecting both shoulders and hips, which greatly limited daily activities. The patient had a past medical history of type 2 diabetes mellitus 
and essential hypertension, and was under medication with metformin 1000 mg twice daily, gliclazide 60mg/day, and lisinopril 20 mg/day.
Physical examination was remarkable for pain with movement and a markedly decreased active range of motion of the shoulder griddle.
Laboratory tests (Table 1) revealed a normochromic, normocytic anaemia, an erythrocyte sedimentation rate (ESR) of 76 mm/h, and a 
C-reactive protein (CRP) 17.9x the upper limit of normal (ULN). The remaining laboratory tests , including serum protein electrophoresis, 
antinuclear antibodies, c and p-ANCAs, complement fractions, rheumatoid factor, and anti-CCP antibody, were unremarkable. Diagnosis of 
PMR was considered and deflazacort 12 mg/day was started. 
.
Table 1. Laboratory test results. Deflazacorte dosage is underlined.
Treatment improved some of the patients’ complaints but failed to achieve complete symptom relief. Laboratory test results showed a mild 
decrease on ESR, with values between 53-59mm/h, while CRP values remained unchanged (Table 1). Deflazacort was then increased to 
18mg/day (with a “tighter” surveillance of glycaemic control) without further improvement.
Prompt investigation was carried out for an alternative diagnosis, and included Prostatic Specific Antigen (PSA), gastrointestinal endoscopy, 
chest x-ray, and abdominal ultrasound, all of which were unremarkable.
Five months later, the patient sought medical care for an acute episode of macroscopic haematuria. Further study with abdominal ultrasound 
(Fig. 1) showed a bladder mass (previously absent) that was confirmed by computed tomography scan to be suggestive of a bladder carcinoma 
extending to the surrounding fatty tissue layer (Fig. 2). 
Radical cystectomy and prostatectomy were carried out and histology confirmed an infiltrative bladder carcinoma – T3bN1M0 – and a 
previously unknown prostate adenocarcinoma – pT2aN0M0, Gleason 6.
A few weeks after surgery, deflazacort was suspended, and one month after discharge, the patient was asymptomatic and his inflammatory 
markers had improved: ESR of 38mm/h and CRP were negative. 
DISCUSSION
Paraneoplastic syndromes affect up to 8% of patients with an active cancer, most of the times preceding its diagnosis[1,2].  
Its pathophysiology is not fully understood, but in the last decades, some mechanisms linking cancer to these syndromes have become 
clearer. It is accepted that soluble factors produced by the tumour and/or an immune/host reaction against tumour cells are involved[1,4]. 
These soluble factors can be peptides or hormones, the latter being the most important mechanism in endocrine paraneoplastic syndromes, 
such as Cushing syndrome. Immune-mediated paraneoplastic syndromes (e.g. rheumatologic paraneoplastic syndromes) are believed to be 
the result of a host’s immunologic response against an underlying neoplasia. It has become clearer that tumour cells can adapt themselves 
in order to evade immunologic-driven destruction, in a process that was named “immunoediting” by Dunn and colleagues[5]. This process 
has three stages: elimination, equilibrium, and escape. In the first stage, the immune response succeeds in eliminating the neoplasm; in the 
second stage, equilibrium between immune destruction and tumour growth is reached, preventing tumour development without eliminating 
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Figure 1: Bladder ultrasound revealing an urothelial carcinoma (white arrow).
Figure 2: Abdominal computed tomography-
scan showing an invasive urothelial 
carcinoma of the bladder (white arrows).
it; and in the last stage, tumour cells manage to evade the immune system control and the tumour grows unrestrained. In the first two stages, 
the likely scenario is of an occult neoplasia and, therefore, patients are often diagnosed with clinical syndromes resulting from the distal 
manifestations of the underlying tumour, such as the case of paraneoplastic PMR.
Diagnosis of paraneoplastic rheumatic syndromes is therefore challenging, and is based on a time-relation scenario and some unusual 
manifestations of the presenting inflammatory musculoskeletal disease, such as rapid/agressive-onset of symptoms, atypical age group, 
poor response to corticosteroids or immunosuppressive therapy, atypical distribution of involved joints, and abnormal laboratory tests.
Commonly associated neoplasms are haematolymphatic malignancies (1/3 of patients), followed by adenocarcinoma of the lung and breast 
(among others)[1,3]. A group of reported cases in the literature linking PMR to malignant neoplasms is summarized in Table 2 - Appendix.
In the present case, the lack of response to treatment and the improvement/resolution of the patient’s complaints after surgery established 
the relationship between PMR and the underlying urothelial cancer/prostate adenocarcinoma, thus leading to the diagnosis of a 
paraneoplastic polymyalgia rheumatica. 
Atypical PMR and, especially the lack of a dramatic treatment response, should prompt additional investigation for alternative diagnosis. 
Recognition of paraneoplastic rheumatic diseases may permit early diagnosis and treatment of the underlying cancer, as these syndromes, 
although rare, can be the first sign of an occult malignancy or its recurrence[3]. 
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Table 2: Reports linking PMR and neoplasm
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